You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Patent: 10,028,940


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,028,940
Title:Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
Inventor(s): Bozik; Michael E. (Pittsburgh, PA), Dworetzky; Steven (Jefferson Hills, PA)
Assignee: Knopp Biosciences LLC (Pittsburgh, PA)
Application Number:15/461,131
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Scope and Claims of United States Patent 10,028,940: A Comprehensive Analysis

Introduction

When analyzing the scope and claims of a patent, such as United States Patent 10,028,940, it is crucial to delve into several key aspects, including the patent's subject matter, the claims' specificity and eligibility, and the broader patent landscape. This article will provide a detailed analysis of these elements, drawing on recent updates and best practices in patent law.

Patent Subject Matter Eligibility

The subject matter eligibility of a patent is a critical factor, especially in the context of recent updates from the USPTO. The 2024 USPTO guidance update on AI patent eligibility is particularly relevant, as it clarifies how AI-related inventions are evaluated.

Evaluating Practical Applications

The USPTO guidance emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, thereby transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The update also clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].

Claim Specificity and Clarity

The specificity and clarity of patent claims are vital to avoid issues such as indefiniteness or impossibility.

Avoiding Indefiniteness

A case in point is the invalidation of a patent due to indefiniteness caused by conflicting terminology in the claims. This highlights the importance of carefully reviewing claims at every step of the prosecution process to ensure that words mean what they are intended to mean and are free of contradictions[2].

Claim Length and Count

Research has shown that narrower claims, measured by independent claim length and count, are associated with a higher probability of grant and a shorter examination process. This suggests that more specific and focused claims can streamline the patent application process[3].

Practical Applications in Claims

Demonstrating practical applications of the claimed method or system is crucial for bolstering the argument for patent eligibility.

Real-World Applications

The 2024 USPTO guidance provides examples where claims are made patent-eligible by specifying real-world applications. For instance, a claim involving an artificial neural network designed to identify anomalies becomes eligible when it demonstrates an improvement in computer technology or provides tangible benefits such as improved noise reduction in audio processing[1].

Patent Scope and Breadth

The scope of a patent is another critical aspect, influencing its validity and enforceability.

Metrics for Measuring Patent Scope

Metrics such as independent claim length and count can be used to measure patent scope. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[3].

Narrowing Claims During Examination

The examination process often narrows the scope of patent claims, making them more specific and focused. This narrowing is more significant when the duration of examination is longer, indicating that more detailed scrutiny leads to more precise claims[3].

The Role of Recent Case Law

Recent case law plays a significant role in shaping the patent landscape and guiding the drafting of patent claims.

Incorporation of Federal Circuit Decisions

The 2024 USPTO guidance integrates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations. This integration promotes consistency and clarity in the application of patent eligibility criteria, reflecting the latest judicial thinking[1].

Global and Public Search Resources

Access to global and public search resources is essential for conducting thorough patent searches and ensuring the novelty and non-obviousness of an invention.

Global Dossier

The Global Dossier service allows users to access file histories of related applications from participating IP Offices, providing a comprehensive view of the patent family and related documentation[4].

Public Search Facility

The USPTO Public Search Facility offers access to patent and trademark information in various formats, including online, microfilm, and print. Trained staff are available to assist users in their searches[4].

Potential for Small Claims Patent Court

The concept of a small claims patent court is being explored to address issues related to patent litigation costs and accessibility.

ACUS Study

The Administrative Conference of the United States (ACUS) has conducted a study on the feasibility and structure of a small claims patent court. This study involves input from a wide range of stakeholders and aims to address legal, policy, and practical considerations[5].

Key Takeaways

  • Subject Matter Eligibility: Ensure that claims integrate judicial exceptions into practical applications to meet patent eligibility criteria.
  • Claim Specificity: Carefully review claims to avoid indefiniteness and ensure they are free of contradictions.
  • Practical Applications: Highlight real-world applications of the claimed method or system to bolster patent eligibility.
  • Patent Scope: Use metrics such as independent claim length and count to measure and narrow patent scope during the examination process.
  • Recent Case Law: Incorporate recent Federal Circuit decisions to ensure consistency and clarity in patent eligibility criteria.
  • Global and Public Search Resources: Utilize resources like the Global Dossier and Public Search Facility to conduct thorough patent searches.

FAQs

Q: How does the 2024 USPTO guidance update impact AI-related patent claims?

A: The update clarifies that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution. It also emphasizes the importance of integrating judicial exceptions into practical applications to meet patent eligibility criteria[1].

Q: What are the consequences of having indefinite or contradictory claims in a patent application?

A: Indefinite or contradictory claims can lead to the invalidation of the patent, as seen in cases where conflicting terminology caused indefiniteness[2].

Q: How can the scope of a patent be measured and optimized?

A: Metrics such as independent claim length and count can be used to measure patent scope. Narrower claims are associated with a higher probability of grant and a shorter examination process[3].

Q: What role does recent case law play in patent eligibility criteria?

A: Recent case law, particularly Federal Circuit decisions, is integrated into the USPTO guidance to provide up-to-date legal standards and interpretations, promoting consistency and clarity in the application of patent eligibility criteria[1].

Q: How can global and public search resources aid in patent searches?

A: Resources like the Global Dossier and Public Search Facility provide comprehensive access to patent and trademark information, helping users ensure the novelty and non-obviousness of an invention[4].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent: Mintz, July 25, 2024.
  2. Patent Invalidated Due To “Impossibility” In The Claims: Wyatt Firm, April 6, 2021.
  3. Patent Claims and Patent Scope: SSRN, September 29, 2016.
  4. Search for patents - USPTO: USPTO, October 18, 2018.
  5. U.S. Patent Small Claims Court: ACUS, April 28, 2022.

More… ↓

⤷  Subscribe

Details for Patent 10,028,940

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Subscribe 2033-08-13
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 ⤷  Subscribe 2033-08-13
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 ⤷  Subscribe 2033-08-13
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 ⤷  Subscribe 2033-08-13
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 ⤷  Subscribe 2033-08-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.